Unique foamable vehicles or carriers comprising at least one wax, waxy substance, counterpart or derivative, a stabilizer, water, and a propellant are provided. In some embodiments, the wax is a liquid wax. In some embodiments, the wax includes a solid wax and a liquid wax. The compositions are substantially free of crystals. The components are selected to provide a composition that is substantially resistant to aging and to phase separation, and/or can substantially solubilize and or stabilize active ingredients. Pharmaceutical and cosmetic compositions with potentially enhanced skin delivery and their uses are also provided.

Unique foamable vehicles or carriers comprising at least one wax, waxy substance, counterpart or derivative, a stabilizer, water, and a propellant are provided. In some embodiments, the wax is a liquid wax. In some embodiments, the wax includes a solid wax and a liquid wax. The compositions are substantially free of crystals. The components are selected to provide a composition that is substantially resistant to aging and to phase separation, and/or can substantially solubilize and or stabilize active ingredients. Pharmaceutical and cosmetic compositions with potentially enhanced skin delivery and their uses are also provided.

A drug delivery system is presented to increase the bioavailability of biopharmaceutic class II, III, or IV active agents.

A drug delivery system is presented to increase the bioavailability of biopharmaceutic class II, III, or IV active agents.

The present invention concerns a compound of formula (I): wherein:—n is an integer comprised between 1 and 7;—X.sub.1 is in particular a radical of formula —CH.sub.2—S—(CH.sub.2).sub.k—S—;—A.sub.1 is in particular a linear or branched alkylene radical comprising from 2 to 30 carbon atoms, and—X.sub.2 is in particular an alkoxy group of formula OR.sub.a, wherein R.sub.a is a linear or branched alkyl group comprising from 1 to 10 carbon atoms.

##STR00001##

The present invention concerns a compound of formula (I): wherein:—n is an integer comprised between 1 and 7;—X.sub.1 is in particular a radical of formula —CH.sub.2—S—(CH.sub.2).sub.k—S—;—A.sub.1 is in particular a linear or branched alkylene radical comprising from 2 to 30 carbon atoms, and—X.sub.2 is in particular an alkoxy group of formula OR.sub.a, wherein R.sub.a is a linear or branched alkyl group comprising from 1 to 10 carbon atoms.

##STR00001##

Provided herein are substituted imidazo[1,2-a]pyridin-2-ylamine compounds, for example, of formula (A), and pharmaceutical compositions thereof; and methods of their use for treating, preventing, or ameliorating one or more symptoms of a Janus kinase-mediated disease.

##STR00001##

Cellulose derivative-polyester composite fibers, matrices including such fibers, and methods for making and using such fibers and matrices are disclosed.

The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.

The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.